Triflusal – 25 mg

Brand:
Cayman
CAS:
322-79-2
Storage:
-20
UN-No:
Non-Hazardous - /

Triflusal is an inhibitor of platelet aggregation (IC50s = 48.3 and 693 µM in isolated human whole blood and platelet-rich plasma, respectively).{52661} It inhibits production of thromboxane B2 (TXB2; Item No. 19030) and 6 keto prostaglandin F1α (6-keto-PGF1α; Item No. 15210) induced by arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) with IC50 values of 468 and 339 µM, respectively, in isolated human whole blood. Triflusal decreases IgG-ovalbumin immune complex-induced NF-κB nuclear translocation and production of nitric oxide (NO) in isolated rat peritoneal macrophages when used at a concentration of 1,000 µM.{8312} Oral administration of triflusal (30 mg/kg) reduces infarct volume and peri-infarct levels of OX-6, a marker of activated microglia, in a rat model of focal ischemia induced by permanent middle cerebral artery occlusion (MCAO).{52662} It also reduces increases in cortical amyloid-β precursor protein (APP) levels induced by intracerebroventricular administration of amyloid-β (25-35) in rats at the same dose.{52663}  

 

Available on backorder

SKU: 30274 - 25 mg Category:

Description

A platelet aggregation inhibitor (IC50s = 48.3 and 693 µM in isolated human whole blood and platelet-rich plasma, respectively); inhibits arachidonic acid-induced TXB2 and PGF1α production (IC50s = 468 and 339 µM, respectively); decreases IgG-ovalbumin immune complex-induced NF-κB nuclear translocation and NO production in isolated rat peritoneal macrophages at 1,000 µM; reduces infarct volume and peri-infarct levels of OX-6 in a rat model of focal ischemia induced by permanent MCAO at 30 mg/kg; reduces increases in APP levels induced by amyloid-β (25-35) in rats at 30 mg/kg


Formal name: 2-(acetyloxy)-4-(trifluoromethyl)-benzoic acid

Synonyms:  UR 1501

Molecular weight: 248.2

CAS: 322-79-2

Purity: ≥98%

Formulation: A crystalline solid